Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

Gil I. Wolfe; Richard J. Barohn; Barbara M. Foster; Carlayne E. Jackson; John T. Kissel; John W. Day; Charles A. Thornton; Sharon P. Nations; Wilson W. Bryan; Anthony A. Amato; Miriam L. Freimer; Gareth J. Parry

doi:10.1002/mus.10224

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

Gil I. Wolfe, Richard J. Barohn, Barbara M. Foster, Carlayne E. Jackson, John T. Kissel, John W. Day, Charles A. Thornton, Sharon P. Nations, Wilson W. Bryan, Anthony A. Amato, Miriam L. Freimer, Gareth J. Parry

Producción científica: Article › revisión exhaustiva

87 Citas (Scopus)

Resumen

We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.

Idioma original	English (US)
Páginas (desde-hasta)	549-552
Número de páginas	4
Publicación	Muscle and Nerve
Volumen	26
N.º	4
DOI	https://doi.org/10.1002/mus.10224
Estado	Published - oct 1 2002

ASJC Scopus subject areas

Clinical Neurology
Physiology (medical)
Cellular and Molecular Neuroscience
Physiology

Acceder al documento

10.1002/mus.10224

Otros archivos y enlaces

Citar esto

@article{6b99cc667e0848ab9ff504b68551b855,

title = "Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis",

abstract = "We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.",

keywords = "Clinical trials, Intravenous immunoglobulin, Myasthenia gravis, Treatment",

author = "Wolfe, {Gil I.} and Barohn, {Richard J.} and Foster, {Barbara M.} and Jackson, {Carlayne E.} and Kissel, {John T.} and Day, {John W.} and Thornton, {Charles A.} and Nations, {Sharon P.} and Bryan, {Wilson W.} and Amato, {Anthony A.} and Freimer, {Miriam L.} and Parry, {Gareth J.}",

year = "2002",

month = oct,

day = "1",

doi = "10.1002/mus.10224",

language = "English (US)",

volume = "26",

pages = "549--552",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley & Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

AU - Wolfe, Gil I.

AU - Barohn, Richard J.

AU - Foster, Barbara M.

AU - Jackson, Carlayne E.

AU - Kissel, John T.

AU - Day, John W.

AU - Thornton, Charles A.

AU - Nations, Sharon P.

AU - Bryan, Wilson W.

AU - Amato, Anthony A.

AU - Freimer, Miriam L.

AU - Parry, Gareth J.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.

AB - We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.

KW - Clinical trials

KW - Intravenous immunoglobulin

KW - Myasthenia gravis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0036789453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036789453&partnerID=8YFLogxK

U2 - 10.1002/mus.10224

DO - 10.1002/mus.10224

M3 - Article

C2 - 12362423

AN - SCOPUS:0036789453

SN - 0148-639X

VL - 26

SP - 549

EP - 552

JO - Muscle and Nerve

JF - Muscle and Nerve

IS - 4

ER -

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto